BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22904680)

  • 21. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
    Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
    Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA; Ito D; Deleo AB; Ferris RL
    Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients.
    Macchioni P; Nicoli D; Casali B; Catanoso M; Farnetti E; Boiardi L; Salvarani C
    Clin Exp Rheumatol; 2007; 25(3):416-21. PubMed ID: 17631738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
    Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
    Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
    Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing.
    Testa R; Bonfigli AR; Salvioli S; Invidia L; Pierini M; Sirolla C; Marra M; Testa I; Fazioli F; Recchioni R; Marcheselli F; Olivieri F; Lanari L; Franceschi C
    Mech Ageing Dev; 2009 Aug; 130(8):497-500. PubMed ID: 19523975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P53 Arg72Pro polymorphism in gastric cancer patients.
    Gomes de Souza L; Miranda de Lima J; Dale Cotrim Guerreiro da Silva I; Manoukian Forones N
    J Gastrointest Cancer; 2009; 40(1-2):41-5. PubMed ID: 19543839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population.
    Song HR; Kweon SS; Kim HN; Piao JM; Yun WJ; Choi JS; Hwang JE; Yoon JY; Kim HR; Park YK; Kim SH; Choi YD; Shin MH
    Gastric Cancer; 2011 Aug; 14(3):242-8. PubMed ID: 21461655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.
    Loeb KR; Asgari MM; Hawes SE; Feng Q; Stern JE; Jiang M; Argenyi ZB; de Villiers EM; Kiviat NB
    PLoS One; 2012; 7(4):e34422. PubMed ID: 22545084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein.
    Ozeki C; Sawai Y; Shibata T; Kohno T; Okamoto K; Yokota J; Tashiro F; Tanuma S; Sakai R; Kawase T; Kitabayashi I; Taya Y; Ohki R
    J Biol Chem; 2011 May; 286(20):18251-60. PubMed ID: 21454683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.
    Proestling K; Hebar A; Pruckner N; Marton E; Vinatzer U; Schreiber M
    PLoS One; 2012; 7(10):e47325. PubMed ID: 23071787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.
    Sullivan A; Syed N; Gasco M; Bergamaschi D; Trigiante G; Attard M; Hiller L; Farrell PJ; Smith P; Lu X; Crook T
    Oncogene; 2004 Apr; 23(19):3328-37. PubMed ID: 15077186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.